Risk factors for recurrence of external genital endometriosis after surgical treatment: prospective cohortant study

Borisova, Anna V.; Козаченко, А. В.; Frankevich, V. E.; Чаговец, В. В.; Kononokhin, A. S.; Стародубцева, Н. Л.; Коган, Е. А.; Adamyan, L. V.

doi:10.21518/2079-701x-2018-7-32-38

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to various sources adenomyosis frequency varies from 12% to 50%. 1,2 The urgency of the problem is stemmed from the widespread of this disease and the complicity of its early diagnosis. Clinical manifestations of adenomyosis are menometrorrhagia and dysmenorrhea, pelvic pain is noted in up to 60%-80% of patients.…”

Section: Introductionmentioning

confidence: 99%

“…3,4 Hysterectomy, which is one of the possible methods of treating adenomyosis with severe clinical symptoms, is used in one-third of cases, since the nodular and diffuse forms of the disease are characterized by the absence of clearly delimited capsule of lesions. [1][2][3] The study of alternative methods of organ-saving treatment of young women with adenomyosis who want to maintain menstrual and reproductive function, with the contraindications for surgical intervention, is especially relevant.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Study of dienogest clinical efficacy in the treatment of adenomyosis

Dobrokhotova

Калиматова

Ilyina

et al. 2021

Journal of Endometriosis and Pelvic Pain Disorders

View full text Add to dashboard Cite

Background: A number of works provide information on the effectiveness of dienogest in uterine adenomyosis. However, information on the use of the drug at various degrees of the adenomatous nodes, is not presented in the available literature. Aim: The aim of the study was to evaluate the clinical efficacy of dienogest in the treatment of patients with adenomyosis 2nd and 3rd stage and chronic pelvic pain. Materials and methods: A comprehensive clinical survey and treatment of 46 patients with signs of adenomyosis were carried out. Patients were divided into two groups: 28 patients with stage 2 adenomyosis, 18 patients with type 3 adenomyosis were included in the 2nd group. On the first phase of the menstrual cycle all patients underwent hysteroscopy for endoscopic verification of the diagnosis using the traditional Karl Storz hysteroscopic stand with separate treatment and diagnostic curettage of the uterine cavity and cervical canal, followed by histological examination. After surgical treatment all patients received dienogest at a dose 2 mg/day for 6 months. The treatment was performed during 6 months. After 3, 6, and 12 months of the study, the patients included in the survey underwent a comprehensive examination with a clinical assessment of the manifestations of the disease. The level of pain manifestations was evaluated on a visual analog scale (VAS) with a range of 0–10 points. During pain assessment, its manifestations were differentiated—pain due to dyspareunia, dysmenorrhea, dyschezia, and chronic pelvic pain were evaluated. Results: In the group of patients with 2nd adenomyosis stage, the intake of dienogest for 6 months led to the absence of manifestations of uterine bleeding and dyschezia, a decrease in the frequency of dyspareunia—by 7.7 times. In patients with the 3rd stage of the disease, the decrease in the symptoms of adenomyosis was less pronounced, however, after taking the drug, a decrease in the frequency of uterine bleeding was found to be 6 times, dyspareunia 4 times, and dyschezia 5 times. Twelve months after the start of observation (6 months after the end of treatment), none of the patients with 2nd stage of disease showed severe pelvic pain, in the group with 3rd stage of adenomyosis there were only two of these patients (11.1%). At the same time, the vast majority of patients included in the study did not have manifestations of chronic pelvic pain—78.6% of patients with 2nd stage of adenomyosis and 55.6% of patients with 3rd stage of disease, the remaining 21.4% and 33.3% of patients of the first and second groups reported a significant decrease in the severity of pain. Conclusions: The inclusion of dienogest in the combined treatment of adenomyosis is clinically effective, contributing to the rapid and reliable relief of the main manifestations of the disease in patients with adenomyosis with grade 2 and 3 nodes. Treatment of adenomyosis with the use of dienogest is clinically effective, contributing to the rapid and reliable relief of the main manifestation of the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Study of dienogest clinical efficacy in the treatment of adenomyosis

Dobrokhotova

Калиматова

Ilyina

et al. 2021

Journal of Endometriosis and Pelvic Pain Disorders

View full text Add to dashboard Cite

show abstract

Features of the expression of sex steroid hormone receptors in first detected and recurrent external genital endometriosis

Ф.Т.¹,

Парамонова²,

Bryunin³

et al. 2022

Probl. reprod.

View full text Add to dashboard Cite

Hormone therapy for patients with endometriosis: status update on the problem (literature review)

Козаченко

2020

Medicinskij sovet

View full text Add to dashboard Cite

Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова; 117997, Россия, Москва, ул. Академика Опарина, д. 4 Резюме Статья посвящена крайне актуальной проблеме лечения эндометриоза, которая является предметом изучения ученых всего мира. Ни в нашей стране, ни за ее рубежами не существует лекарственного средства, обладающего 100% эффективностью в отношении эндометриоидных гетеротопий и лишенного выраженных побочных действий. В дополнение к этому доказательная база, полученная при проведении рандомизированных клинических исследований по эффективности лекарственной терапии эндометриоза, не обладает достаточным качеством с позиции методологии проведения исследования. В российских клинических рекомендациях по лечению эндометриоза постулировано, что оперативное вмешательство является основным этапом в лечении этого заболевания. Задачи лечения эндометриоза состоят в удалении эндометриоидного очага, уменьшении интенсивности болей, лечении бесплодия, предотвращении прогрессирования и профилактике рецидивов заболевания. В настоящее время отсутствует универсальная медикаментозная терапия эндометриоза, а применяемое лекарственное лечение является неспецифическим и направлено преимущественно на уменьшение выраженности имеющихся симптомов. Лекарственное лечение эндометриоза подбирают индивидуально, в зависимости от степени распространения заболевания, клинической симптоматики и потребностей самой пациентки. Помимо указанного при выборе гормональной терапии эндометриоза следует принимать во внимание эффективность лекарственного средства, его индивидуальную переносимость, стоимость лечения, опыт врача в лечении этим препаратом, выполнение пациенткой рекомендаций доктора. В статье приведены возможные алгоритмы выбора стратегии лечения эндометриоза хирургическими и медикаментозными средствами. Рассмотрены принципы и особенности действия гормональных препаратов, предназначенных для лечения эндометриоза. Проведен обзор и анализ современных клинических данных, касающихся проблемы лечения эндометриоза. Ключевые слова: эндометриоз, наружный генитальный эндометриоз, диеногест, гормональная терапия эндометриоза, дидрогестерон Для цитирования: Козаченко А.В. Гормональная терапия больных эндометриозом-современное состояние проблемы (обзор литературы).

show abstract

Risk factors for recurrence of external genital endometriosis after surgical treatment: prospective cohortant study

Cited by 5 publications

References 10 publications

Study of dienogest clinical efficacy in the treatment of adenomyosis

Study of dienogest clinical efficacy in the treatment of adenomyosis

Features of the expression of sex steroid hormone receptors in first detected and recurrent external genital endometriosis

Hormone therapy for patients with endometriosis: status update on the problem (literature review)

Contact Info

Product

Resources

About